Skip to main content
    Intuitive Surgical logo

    Intuitive Surgical

    Health care

    TickerISRGISINUS46120E6023

    Intuitive Surgical stock analysis: how the business works, what moves it and what to check

    How Intuitive Surgical makes money, what moves the stock, which figures to check and the risks to keep in view.

    Peakwise Research · · Updated · 4 min read

    Contents

    Intuitive Surgical makes the da Vinci robotic surgery system. Most of its revenue does not come from selling robots but from the instruments and service used in every procedure, which makes procedure growth the number to watch.

    CompanyIntuitive Surgical, Inc.
    TickerISRG
    ListingNasdaq
    SectorHealth Care
    ISINUS46120E6023
    HeadquartersSunnyvale, California, USA

    Intuitive Surgical at a glance

    • Maker of the da Vinci surgical robot.
    • Most revenue is recurring: instruments, accessories and service.
    • High valuation reflects its market leadership.

    A short history

    Intuitive Surgical was founded in 1995, building on research at SRI International. The da Vinci system received FDA approval in 2000 and has since been used in millions of procedures. The latest generation, da Vinci 5, launched in 2024.

    How Intuitive Surgical makes money

    Intuitive sells and leases da Vinci systems and the Ion system for lung biopsies. The larger, recurring part of revenue comes from instruments and accessories used in each procedure plus service contracts.

    Competitive position

    Intuitive has a large installed base, decades of clinical data and many surgeons trained on its systems. Each procedure uses instruments that bring recurring revenue. Competitors include Medtronic, Johnson & Johnson and CMR Surgical, but none has reached comparable scale.

    What moves Intuitive Surgical stock

    • Procedure growth. Worldwide da Vinci procedures drive recurring revenue.
    • New system cycle. The da Vinci 5 launch and upgrades.
    • International expansion. More hospitals outside the US.
    • Competition. New surgical robots from Medtronic and others.

    Intuitive Surgical key figures, up to date

    ISRG

    The AI stock analysis computes these figures from current market data, with a short comment on each number and the method behind the fair value range.

    Free for 7 days. Not investment advice.

    The numbers worth checking

    Not every ratio matters equally for every company. For Intuitive Surgical, these are the figures that tell you the most. If a term is new, the guides on the P/E ratio and fair value explain the basics.

    • Worldwide procedure growth. The core metric each quarter.
    • Installed base. Number of systems in use.
    • Recurring revenue share. Instruments, accessories and service.
    • Valuation. Trades at a high multiple of earnings.

    The best source for these figures is the latest annual or quarterly report on the Intuitive Surgical investor relations site. Our guide on how to read an earnings report shows where to find them.

    How to think about valuation

    Intuitive trades at a high P/E. Investors focus on procedure growth, because it drives recurring revenue, and on system placements.

    Opportunities

    • Procedure growth. More types of surgery are performed robotically.
    • da Vinci 5. A new system generation drives upgrades.
    • International. Room for growth outside the US.

    Risks to keep in view

    • Competition. Other robots could win price-sensitive hospitals.
    • Hospital budgets. Capital purchases slow when hospitals are under pressure.
    • Tariffs and supply chain. Manufacturing in Mexico and other countries.

    A useful exercise is to write the bull case and the bear case for Intuitive Surgical in three sentences each. If you cannot fill the bear case, you have not looked hard enough. How to write an investment thesis walks through it.

    What to watch in the next report

    • Worldwide procedure growth
    • System placements
    • Gross margin and tariff effects

    How to research Intuitive Surgical stock with Peakwise

    The quickest way to put the points above against current figures is the AI stock analysis: search for Intuitive Surgical, generate the report and check the executive summary, the financials and the fair value range. The report states the method behind its estimate, so you can see which assumptions drive it.

    For anything the report leaves open, ask the investment chatbot. It runs a web search for each question and links the sources it used, so you can open them and check. A good first question:

    How fast did worldwide da Vinci procedures grow last quarter and how many da Vinci 5 systems were placed?

    To look at the chart itself, the AI chart analysis describes trend, support and resistance levels and patterns over one month, one year and the full history.

    This article describes the business and the questions worth asking. It contains no price targets and no forecasts, and it is not investment advice. Check current figures before you make a decision.

    Frequently asked questions

    From selling or leasing robots and, more importantly, from instruments, accessories and service that recur with every procedure.

    That depends on your goals, your time horizon and the price you pay, so no article can answer it for you. For Intuitive Surgical, the points that carry the most weight are procedure growth, new system cycle and, on the risk side, competition. Check them with current figures and decide for yourself. This is not investment advice.

    Competition. Other robots could win price-sensitive hospitals. Hospital budgets. Capital purchases slow when hospitals are under pressure. Tariffs and supply chain. Manufacturing in Mexico and other countries.

    Intuitive Surgical, Inc. trades under the ticker ISRG. The ISIN is US46120E6023. Listing: Nasdaq.

    Check Intuitive Surgical yourselfin one report

    The AI stock analysis puts financials, news, analyst consensus, a fair value range with its method, and risks and opportunities in one report.

    Free for 7 days. Not investment advice.